A recent court victory that allows a South African company to produce a cheaper cancer drug will reduce prices significantly only if such medicines were more widely available.

Cancer researcher Prof Paul Ruff says significant price reductions would happen if the wider public were included. “Only 15% of the population have health insurance, and of that only 5% have access to comprehensive insurance,” he says...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.